Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Graphene quantum dot as therapeutic agent for disease associated with abnormal fibrillation or aggregation of neuroprotein

A technology of graphene quantum dots and neural proteins, which is used in neurological diseases, graphene, metabolic diseases, etc.

Active Publication Date: 2021-02-12
生物石墨烯有限公司 +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, there is no therapeutic agent that can be substantially used for the treatment of synucleinopathies and has a significant effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Graphene quantum dot as therapeutic agent for disease associated with abnormal fibrillation or aggregation of neuroprotein
  • Graphene quantum dot as therapeutic agent for disease associated with abnormal fibrillation or aggregation of neuroprotein
  • Graphene quantum dot as therapeutic agent for disease associated with abnormal fibrillation or aggregation of neuroprotein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0076]Example: Preparation of Graphene Quantum Dots (GQDs)

[0077]After adding carbon fiber (0.9g) to a mixed solution of sulfuric acid (300ml) and nitric acid (100ml), it was heated at 80°C for 24 hours (thermo-oxidation process, see Fig. 1). Then, it was diluted with deionized water, and then, the regenerated nitrocellulose membrane (Cat#:06-680-2G; MWCO 1,000 Dalton; Fisher Sicentific) was used for dialysis to completely remove the acid and excess carbon. Clear. Then, the GQD solution was vacuum filtered using a porous inorganic membrane filter (Cat#: 6809-5002; Whatman-Anodisc 47; GE Healthcare) to remove large particles. Then, the solution is rotary evaporated to obtain graphene quantum dots (GQDs) in powder form. The obtained graphene quantum dots contain all the graphitic domains and edge functional groups. The main element components are nitrogen (N), carbon (C), hydrogen (H), and sulfur (S). ) And oxygen (O) were subjected to elemental analysis (EA). The elemental analysis wa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a graphene quantum dot as a therapeutic agent for diseases associated with abnormal fibrillation or aggregation of neuroproteins. The graphene quantum dot according to the present invention suppresses alfa-syn fibrillation or disaggregates already formed alfa-syn fibrils, and shows the working effect of passing through the blood brain barrier (BBB). Therefore, the graphene quantum dot according to the present invention can be advantageously used as a therapeutic agent for diseases associated with abnormal fibrillation or aggregation of neuroproteins, such as neurodegenerative diseases, inflammatory diseases, and metabolic diseases.

Description

Technical field[0001]The invention relates to a graphene quantum dot and its use. Specifically, it relates to a graphene quantum dot used as a therapeutic agent for degenerative neurological diseases, inflammatory diseases or metabolic diseases related to abnormal fibrosis or aggregation of neuroproteins and its use.Background technique[0002]α-synuclein (α-syn), as a rich protein in the human brain, is mainly found in the ends of nerve cells (neurons). In this structure, it interacts with phospholipids and proteins . If α-syn is abnormally aggregated, α-syn fibrils (α-syn fibrils; α-syn PFFs) will be formed. Affected by this α-syn fibril, synucleinopathy, that is, degenerative neurological disease, metabolic disease, etc. will occur. Therefore, therapeutic agents have been developed, which can treat degenerative neurological diseases, metabolic diseases, etc. by inhibiting the fibrillation of α-syn or decomposing the formed α-syn fibrils (Korean Patent 10-2018 -0081465). However, un...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/44A61P25/00A61P29/00A61P3/00
CPCA61K33/44A61P3/00A61P25/00A61P29/00C09K11/65B82Y30/00C01B32/184C01P2004/64C01P2002/82B82Y5/00C01B32/182C01B2204/32C01P2004/02C01P2004/04C01P2006/60
Inventor 洪秉熙柳济民
Owner 生物石墨烯有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com